Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 3
1995 10
1996 15
1997 15
1998 17
1999 33
2000 35
2001 53
2002 80
2003 66
2004 77
2005 86
2006 72
2007 82
2008 108
2009 132
2010 134
2011 143
2012 136
2013 153
2014 149
2015 147
2016 151
2017 120
2018 115
2019 116
2020 117
2021 128
2022 114
2023 7
Text availability
Article attribute
Article type
Publication date

Search Results

2,377 results
Results by year
Filters applied: . Clear all
Page 1
Multiple Sclerosis.
Reich DS, Lucchinetti CF, Calabresi PA. Reich DS, et al. N Engl J Med. 2018 Jan 11;378(2):169-180. doi: 10.1056/NEJMra1401483. N Engl J Med. 2018. PMID: 29320652 Free PMC article. Review. No abstract available.
Pregnancy and multiple sclerosis: an update.
Varytė G, Arlauskienė A, Ramašauskaitė D. Varytė G, et al. Curr Opin Obstet Gynecol. 2021 Oct 1;33(5):378-383. doi: 10.1097/GCO.0000000000000731. Curr Opin Obstet Gynecol. 2021. PMID: 34310364 Free PMC article. Review.
Teriflunomide and fingolimod are not recommended during breastfeeding, however, glatiramer acetate and IFN-beta are considered to be safe. SUMMARY: The evidence of potential fetotoxicities and adverse pregnancy outcomes associated with DMTs is increasing, although m …
Teriflunomide and fingolimod are not recommended during breastfeeding, however, glatiramer acetate and IFN-beta are considered …
Pregnancy and Family Planning in Multiple Sclerosis.
Langer-Gould AM. Langer-Gould AM. Continuum (Minneap Minn). 2019 Jun;25(3):773-792. doi: 10.1212/CON.0000000000000745. Continuum (Minneap Minn). 2019. PMID: 31162316 Review.
RECENT FINDINGS: Recent studies indicate that most women diagnosed with MS today can have children, breast-feed, and resume beta interferons or glatiramer acetate per their preferences without incurring an increased risk of relapses during the postpartum period. ... …
RECENT FINDINGS: Recent studies indicate that most women diagnosed with MS today can have children, breast-feed, and resume beta interferons …
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. Brown JWL, et al. JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588. JAMA. 2019. PMID: 30644981 Free PMC article.
EXPOSURES: The use, type, and timing of the following DMTs: interferon beta, glatiramer acetate, fingolimod, natalizumab, or alemtuzumab. After propensity-score matching, 1555 patients were included (last follow-up, February 14, 2017). ...The probability of conversi …
EXPOSURES: The use, type, and timing of the following DMTs: interferon beta, glatiramer acetate, fingolimod, natalizumab, or a …
Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Li H, Hu F, Zhang Y, Li K. Li H, et al. J Neurol. 2020 Dec;267(12):3489-3498. doi: 10.1007/s00415-019-09395-w. Epub 2019 May 25. J Neurol. 2020. PMID: 31129710 Review.
The risk ratios with 95% credible intervals were as follows: alemtuzumab, 0.49 (0.40, 0.59); ocrelizumab, 0.49 (0.40, 0.61); mitoxantrone, 0.47 (0.27, 0.80); natalizumab, 0.51 (0.43, 0.61); fingolimod, 0.57 (0.50, 0.65); peginterferon beta-1a, 0.63 (0.52, 0.77); dimethyl fumarate …
The risk ratios with 95% credible intervals were as follows: alemtuzumab, 0.49 (0.40, 0.59); ocrelizumab, 0.49 (0.40, 0.61); mitoxantrone, 0 …
Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions.
Zinger N, Ponath G, Sweeney E, Nguyen TD, Lo CH, Diaz I, Dimov A, Teng L, Zexter L, Comunale J, Wang Y, Pitt D, Gauthier SA. Zinger N, et al. Neurol Neuroimmunol Neuroinflamm. 2022 Jan 19;9(2):e1138. doi: 10.1212/NXI.0000000000001138. Print 2022 Mar. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35046083 Free PMC article.
BACKGROUND AND OBJECTIVES: To determine the effects of dimethyl fumarate (DMF) and glatiramer acetate on iron content in chronic active lesions in patients with multiple sclerosis (MS) and in human microglia in vitro. METHODS: This was a retrospective observational …
BACKGROUND AND OBJECTIVES: To determine the effects of dimethyl fumarate (DMF) and glatiramer acetate on iron content in chron …
Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.
Coyle PK, Gocke A, Vignos M, Newsome SD. Coyle PK, et al. Adv Ther. 2021 Jul;38(7):3550-3588. doi: 10.1007/s12325-021-01761-3. Epub 2021 Jun 1. Adv Ther. 2021. PMID: 34075554 Free PMC article. Review.
Data suggest that some classes of DMT, including type 1 interferons and glatiramer acetate, may not significantly impair the response to vaccination. ...
Data suggest that some classes of DMT, including type 1 interferons and glatiramer acetate, may not significantly impair the r …
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis.
Roos I, Leray E, Casey R, Horakova D, Havrdova E, Izquierdo G, Madueño SE, Patti F, Edan G, Debouverie M, Pelletier J, Ozakbas S, Amato MP, Clavelou P, Grammond P, Boz C, Buzzard K, Skibina O, Ciron J, Gerlach O, Grand'Maison F, Lechner-Scott J, Malpas C, Butzkueven H, Vukusic S, Kalincik T; MSBase and OFSEP Study Groups. Roos I, et al. Neurology. 2021 Aug 31;97(9):e869-e880. doi: 10.1212/WNL.0000000000012354. Epub 2021 Jun 30. Neurology. 2021. PMID: 34193589
METHODS: Patients treated with high-efficacy (natalizumab, alemtuzumab, mitoxantrone, ocrelizumab, rituximab, cladribine, fingolimod) or low-efficacy (interferon beta, glatiramer acetate, teriflunomide) therapies after SPMS onset were selected from MSBase and Observ …
METHODS: Patients treated with high-efficacy (natalizumab, alemtuzumab, mitoxantrone, ocrelizumab, rituximab, cladribine, fingolimod) or low …
Nicolau syndrome caused by Glatiramer.
Ciprian S, Lava SAG, Milani GP, Bianchetti MG, Consolascio D, Lardelli PF. Ciprian S, et al. Mult Scler Relat Disord. 2022 Jan;57:103365. doi: 10.1016/j.msard.2021.103365. Epub 2021 Nov 2. Mult Scler Relat Disord. 2022. PMID: 35158471 Free article.
Injection-site reactions to glatiramer are common and include erythema, pruritus, pain, or induration. Additionally, the present systematic review of the literature documents 20 cases of Nicolau syndrome following glatiramer, a rare but potentially severe skin react …
Injection-site reactions to glatiramer are common and include erythema, pruritus, pain, or induration. Additionally, the present syst …
Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.
Landmeyer NC, Bürkner PC, Wiendl H, Ruck T, Hartung HP, Holling H, Meuth SG, Johnen A. Landmeyer NC, et al. Neurology. 2020 Jun 2;94(22):e2373-e2383. doi: 10.1212/WNL.0000000000009522. Epub 2020 May 19. Neurology. 2020. PMID: 32430312
Twenty-five studies were related to platform therapies (mainly beta-interferon [n = 17] and glatiramer acetate [n = 4]), whereas 22 studies were related to escalation therapies (mainly natalizumab [n = 14] and fingolimod [n = 6]). ...
Twenty-five studies were related to platform therapies (mainly beta-interferon [n = 17] and glatiramer acetate [n = 4]), where …
2,377 results